<DOC>
	<DOCNO>NCT01931878</DOCNO>
	<brief_summary>The purpose research study compare safety effectiveness local injection botulinum toxin A ( XeominÂ® ) inactive test substance ( placebo ) medical condition call Restless Leg Syndrome . This study double blind cross design . Cross mean two set injection . The first set injection either Xeomin placebo . The order injection reverse three month point follow first injection . Double blind mean neither investigator know one two ( Xeomin placebo ) receive .</brief_summary>
	<brief_title>Investigation Efficacy incobotulinumtoxinA ( Xeomin ) Relieving Symptoms Restless Leg Syndrome .</brief_title>
	<detailed_description>Please contact PI detail clinical study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<criteria>Subjects 18 80 year age , sex , race ethnic group . Diagnosis restless legs syndrome Disease duration longer 3 month Restless Leg Syndrom Rating Scale score 11 ( moderate ) Subjects eligible treated botulinum toxin therapeutic reason base upon physician ' clinical experience . Subjects able read , speak , understand English . Existing significant acute medical condition ( i.e . cardiovascular , endocrine , hematologic , neoplastic , infectious , autoimmune disorder ) . Pregnancy plan pregnancy ( determined urine pregnancy test ) . Women childbearing age use reliable mode contraception study period ( abstinence , etc ) . Active breast feeding . Enrollment clinical trial ( currently within past 3 month ) treatment impose protocol . Any subject botulinum toxin treatment would contraindicate ; know allergy sensitivity medication . Subjects young 18 year age . Neuromuscularjunction disorder . Evidence acute pathology neuroimaging . Axis I diagnosis determined neurologist psychiatrist . Anesthetic medication within two week corticosteroid injection within 4 week enrollment . Subject receive botulinum toxin injection past 4 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Restless Legs Syndrome</keyword>
	<keyword>Leg pain</keyword>
	<keyword>Sleep</keyword>
	<keyword>Dysesthesias</keyword>
	<keyword>incobotulinumtoxin</keyword>
</DOC>